| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD.
Address correspondence and reprint requests to Dr. T.N. Chase, Experimental Therapeutic Branch, Bldg. 10, Rm. 5C103, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892-1406.
Background:— Serotoninergic transmission in the basal ganglia is known to influence dopaminergic mechanisms and motor function.
Objective:— To evaluate the possibility that serotoninergic 5-HT1A autoreceptors (by regulating the release of serotonin as well as dopamine formed from exogenous levodopa) affect the response alterations complicating levodopa treatment of PD.
Methods:— The 5-HT1A receptor agonist sarizotan (EMD128130) was systemically administered alone and together with levodopa to parkinsonian rats and nonhuman primates.
Results:— In 6-hydroxydopamine-lesioned rats, sarizotan (2.5 mg/kg PO) had no effect on the acute rotational response to levodopa but did attenuate the shortening in motor response duration induced by chronic levodopa treatment. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys, sarizotan (2 mg/kg PO) alone had no effect on parkinsonian severity or on the antiparkinsonian response to levodopa. In contrast, the same dose of sarizotan reduced levodopa-induced choreiform dyskinesias by 91 ± 5.9%. In both species, the motoric effects of sarizotan were blocked by the selective 5-HT1A antagonist WAY100635 (0.1 mg/kg SC), indicating that the observed sarizotan responses were probably mediated at the 5-HT1A autoreceptor.
Conclusion:— Pharmaceuticals acting to stimulate 5-HT1A receptors could prove useful in the treatment of the motor response complications in parkinsonian patients.
This article has been cited by other articles:
|
|
 |
|
  C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, December 1, 2008; 131(12): 3380 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Milak, A. J. Severance, R. T. Ogden, J. Prabhakaran, J.S. D. Kumar, V. J. Majo, J. J. Mann, and R. V. Parsey Modeling Considerations for 11C-CUMI-101, an Agonist Radiotracer for Imaging Serotonin 1A Receptor In Vivo with PET J. Nucl. Med., April 1, 2008; 49(4): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Iravani, K. Tayarani-Binazir, W. B. Chu, M. J. Jackson, and P. Jenner In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor Disability J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1225 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Bonuccelli and P. Del Dotto New pharmacologic horizons in the treatment of Parkinson disease. Neurology, October 10, 2006; 67(7 Suppl 2): S30 - S38. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Lane, S. Cheetham, and P. Jenner Dopamine Uptake Inhibitor-Induced Rotation in 6-Hydroxydopamine-Lesioned Rats Involves Both D1 and D2 Receptors but Is Modulated through 5-Hydroxytryptamine and Noradrenaline Receptors J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1124 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, D. Cussac, A. Gobert, F. Lejeune, J.-M. Rivet, C. M. La Cour, A. Newman-Tancredi, and J.-L. Peglion S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 903 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Durif, B. Debilly, M. Galitzky, D. Morand, F. Viallet, M. Borg, S. Thobois, E. Broussolle, and O. Rascol Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study Neurology, February 10, 2004; 62(3): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Iravani, M. J. Jackson, M. Kuoppamaki, L. A. Smith, and P. Jenner 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates J. Neurosci., October 8, 2003; 23(27): 9107 - 9115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Madhavan, W. J. Freed, V. Anantharam, and A. G. Kanthasamy 5-Hydroxytryptamine 1A Receptor Activation Protects against N-Methyl-D-aspartate-Induced Apoptotic Cell Death in Striatal and Mesencephalic Cultures J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier, and M. J. Millan Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
